Drugs / Rev-56
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07709494 | Jul 2026 → Jun 2027 expected | bronchiectasis | Revagenix, Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | Revagenix, Inc. | Revagenix Doses First Participant in Phase 1 Trial of Rev-56, an Inhaled Therapy for Non-CF Bronchiectasis revagenix.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rev-56 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709494 ↗ |
| Route | Inhaled | “administered by inhalation via an investigational nebulizer device” NCT07709494 ↗ |